These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36927963)

  • 21. Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004-2012: a cohort study.
    Mberi MN; Kuonza LR; Dube NM; Nattey C; Manda S; Summers R
    BMC Health Serv Res; 2015 Jul; 15():259. PubMed ID: 26141729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy.
    Surial B; Chammartin F; Damas J; Calmy A; Haerry D; Stöckle M; Schmid P; Bernasconi E; Fux CA; Tarr PE; Günthard HF; Wandeler G; Rauch A;
    Clin Infect Dis; 2023 Sep; 77(5):729-737. PubMed ID: 37157869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda.
    Kiwanuka J; Mukulu Waila J; Muhindo Kahungu M; Kitonsa J; Kiwanuka N
    PLoS One; 2020; 15(4):e0217606. PubMed ID: 32255796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
    Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Hirasen K; van den Berg L; Miot J; Long LC; Fox MP
    Drug Saf; 2018 Dec; 41(12):1343-1353. PubMed ID: 30043384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
    Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
    PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.
    Squillace N; Lorenzini P; Lapadula G; Bandera A; Cozzi-Lepri A; Rusconi S; Puoti M; Castagna A; Antinori A; Gori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2016 Sep; 71(9):2663-9. PubMed ID: 27272727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
    Brown TT; Cole SR; Li X; Kingsley LA; Palella FJ; Riddler SA; Visscher BR; Margolick JB; Dobs AS
    Arch Intern Med; 2005 May; 165(10):1179-84. PubMed ID: 15911733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
    The RESPOND Study Group
    AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.
    Tien PC; Schneider MF; Cole SR; Levine AM; Cohen M; DeHovitz J; Young M; Justman JE
    AIDS; 2007 Aug; 21(13):1739-45. PubMed ID: 17690572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and incidence of pre-diabetes and diabetes mellitus among people living with HIV in Ghana: Evidence from the EVERLAST Study.
    Sarfo FS; Norman B; Nichols M; Appiah L; Osei Assibey S; Tagge R; Ovbiagele B
    HIV Med; 2021 Apr; 22(4):231-243. PubMed ID: 33174302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
    Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
    J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.
    Bakal DR; Coelho LE; Luz PM; Clark JL; De Boni RB; Cardoso SW; Veloso VG; Lake JE; Grinsztejn B
    J Antimicrob Chemother; 2018 Aug; 73(8):2177-2185. PubMed ID: 29722811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.
    Ursenbach A; Max V; Maurel M; Bani-Sadr F; Gagneux-Brunon A; Garraffo R; Ravaux I; Robineau O; Makinson A; Rey D;
    J Antimicrob Chemother; 2020 Nov; 75(11):3344-3348. PubMed ID: 32791523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter cohort study of diabetes mellitus and impaired fasting glucose in HIV-infected patients in China.
    Zhang C; Chow FC; Han Y; Xie J; Qiu Z; Guo F; Li Y; Wang H; Li T
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):298-303. PubMed ID: 25469524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.
    Alvarez-Uria G; Naik PK; Pakam R; Midde M
    Glob Health Action; 2013 Sep; 6():21682. PubMed ID: 24028937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
    Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G
    AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
    Verburgh ML; Wit FWNM; Boyd A; Reiss P; Van der Valk M;
    AIDS; 2023 Oct; 37(12):1843-1850. PubMed ID: 37433218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.